2024 CSCO|Disitamab Vedotin Combined with Camrelizumab and S-1 as Perioperative Therapy for Gastric Cancer Showed Promising Efficacy with a pCR Rate of 30% 2024 ESMO | Disitamab Vedotin Achieves 33 Months OS as First-Line Treatment of Advanced Urothelial Carcinoma ...
antibody-drug conjugate (ADC) platform and bifunctional antibody (HiBody) platform. Our technology platforms enable the discovery, screening and development of new molecules and proprietary
Telitacicept is the first biological drug for dual-target treatment of systemic lupus erythematosus in the world. In March 2021, the new drug marketing application of Telitacicept for the treatment of SLE passed the priority review and approval process. As an urgently needed clinical drug with o...
雪球为您提供荣昌生物制药(01307)股票实时行情,资金流向,新闻资讯,研究报告,社区互动,交易信息,个股点评,公告,财务指标分析等与荣昌生物制药(01307)股票相关的信息与服务.
荣昌生物是一家始终坚持创新、不断追求科学卓越的公司。在这样一个机遇与挑战并重的平台上,每个人都能够得到足够的尊重与信任。它的开放与包容能够吸引更多优秀人才的加入,海内外业务的扩展,让我有更多机会深入了解行业。同时也让我看到周围更多优秀的同事,他们怀抱激情和理想,始终以专业的态度对待各项工作,散发各自的闪...
Vedotin from later-line treatment to first-line treatment, bringing better survival benefits for more patients.
荣昌生物制药(烟台)股份有限公司由王威东先生领导的烟台荣昌制药股份有限公司和留美科学家房健民博士于2008年共同创立。荣昌生物总部位于中国山东省烟台市,在中国和美国均设有实验研究机构和办事处。荣昌生物致力于发现、开发、生产和商业化同类首创、同类最佳的生物药物,针对自身免疫、肿瘤、眼科等重大疾病领域创制出一批具...
荣昌生物制药是荣昌生物制药(烟台)股份有限公司旗下品牌。荣昌生物制药(烟台)股份有限公司创设于2008年07月04日,公司地址位于中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号,地理条件好;主要经营领域有研发、生产和销售医药产品、诊断试剂产品,以及进行与上述产品及其研发相关的技术服务、技术转让,货物或技术进...
Our vision is to become a leading world-class bio-pharmaceutical company in both China and the world. We have also established our Scientific Advisory Board which currently comprises five renowned professors and key opinion leaders in the areas of our research and development, including Dr. Pei Ga...